Recent studies have shown that sialylated neolacto-GSLs can sterically hinder human leucocyte antigen class I (HLA-I) interactions and suppress CD8+ T cell activation, suggesting a role in tumor immune evasion.26 This evidence concerns the gene CD8A and neoplasm.